As with any targeted therapy, ALK-driven NSCLC tumor cells inevitably acquire drug resistance, leading to clinical relapse. At the present time, ALK inhibitors have not yet been approved for use in other ALK-driven cancers than NSCLC; however, some studies have reported remarkable responses, and...